Skip to main content
Clinical Trials/DRKS00031999
DRKS00031999
Completed
未知

Application of saliva markers for the in vivo testing of dosage forms

Institut für Pharmazie - Biopharmazie & Pharmazeutische Technologie0 sites12 target enrollmentAugust 28, 2023

Overview

Phase
未知
Intervention
Not specified
Conditions
Determination of the gastric residence time of a new formulation compared to an established formulation
Sponsor
Institut für Pharmazie - Biopharmazie & Pharmazeutische Technologie
Enrollment
12
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 28, 2023
End Date
April 25, 2019
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Institut für Pharmazie - Biopharmazie & Pharmazeutische Technologie

Eligibility Criteria

Inclusion Criteria

  • Ethnic origin: Caucasian
  • \-BMI: \> 18 kg/m² and \< 30 kg/m²
  • \-Minimum weight: 50 kg
  • \-Good health, judged by the investigator not to deviate from the norm in clinical terms
  • \-Presentation of written informed consent

Exclusion Criteria

  • \- Disorders/diseases affecting the swallowing process (e.g. severe dysphagia with regard to food and/or solid oral dosage forms).
  • \- claustrophobia
  • \- Gastrointestinal disease and/or pathological changes that may interfere with gastric emptying.
  • \- Known or suspected stenosis, fistulae or mechanical obstruction within the gastrointestinal tract.
  • \- surgical procedures on the gastrointestinal tract within the last 12 months
  • \- inflammatory bowel disease (Crohn's disease, ulcerative colitis or diverticulitis)
  • \- implanted or portable electromechanical medical devices such as a pacemaker, defibrillator or infusion pump
  • \- Known allergies or intolerances to the ingredients of the standard meal
  • \- Individuals who are unable to consume an appropriately sized portion of a meal in a given amount of time
  • \- Alcohol or drug addiction

Outcomes

Primary Outcomes

Not specified

Similar Trials